Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
In this episode, Julia LaBarbera, MSN, RN, AGACNP-BC, discusses the latest evidence and guidance on how advanced practice providers can optimize patient outcomes with CDK4/6 inhibitors for HR+/HER2- breast cancer. Topics include:
- An overview of the monarchE study leading to FDA approval of adjuvant abemaciclib
- Key trial data on abemaciclib, palbociclib, and ribociclib for metastatic HR+/HER2- breast cancer
- Managing adverse events associated with CDK4/6 inhibitors
- Promoting adherence to oral therapy
Presenter:
Julia LaBarbera, MSN, RN, AGACNP-BC
Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California
Link to full program:
PCE.is/Onc22
